A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy Review uri icon


MeSH Major

  • Biological Factors
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a group of idiopathic, acquired, immune-mediated inflammatory demyelinating diseases of the peripheral nervous system. A majority of patients with CIDP respond to "first-line" treatment with IVIG, plasmapheresis and/or corticosteroids. There exists insufficient evidence to ascertain the benefit of treatment with "conventional" immunosuppressive drugs. The inconsistent efficacy, long-term financial burden and health risks of non-specific immune altering therapy have drawn recurrent attention to the possible usefulness of a variety of biological agents that target key aspects in the CIDP immunopathogenic pathways. This review aims to give an updated account of the scientific rationale and potential use of biological therapeutics in patients with CIDP. No specific treatment recommendations are given. The discovery, development and application of biological markers by modern molecular diagnostic techniques may help identify drug-na├»ve or treatment-resistant CIDP patients most likely to respond to targeted immunotherapy.

publication date

  • January 18, 2013



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jns.2013.01.003

PubMed ID

  • 23337197

Additional Document Info

start page

  • 1

end page

  • 9


  • 326


  • 1-2